Phenylpropanolamine
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
- Phenylpropanolamine
- Phenylpropanolamine: From Registered Oral Decongestant Products to Nasal Cavity Disease
Phenylpropanolamine: From Registered Oral Decongestant Products to Nasal Cavity Disease
One-Sentence Summary
Phenylpropanolamine is an oral sympathomimetic marketed in South Africa in several cold and sinus products. The approved indication text is not recorded in the registration data. The TxGNN model predicts it may be effective for nasal cavity disease, but 0 clinical trials and 0 publications currently support this prediction. This may reflect a known decongestant use rather than true repurposing, and there are serious safety concerns.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the registration data |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 6 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the dataset. Phenylpropanolamine is generally described as an alpha-adrenergic agonist and indirect sympathomimetic. It constricts blood vessels in the nasal mucosa, which reduces swelling and congestion. This makes the link to nasal cavity disease mechanistically plausible.
The high score most likely reflects an existing decongestant use, not a new therapeutic direction. The registered product names (for example Sinutab and Flustat) are consistent with this. The label should be checked before this is treated as a true repurposing candidate.
The other four predictions are weak or implausible. Acute laryngopharyngitis has only an indirect symptomatic link. Rosacea conjunctivitis, faucial diphtheria and cervical disc degenerative disorder have no plausible mechanism and are probably knowledge-graph artefacts.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
Six registrations are recorded in total. Details are available for the five below. The approved indication text is not recorded for any of them.
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 27/5.8/0101 | Sinuclear | Capsule | Not recorded |
| Reg. No. Z/5.8/360 | Sinustat | Capsule | Not recorded |
| Reg. No. F/5.8/275 | Sinutab | Tablet | Not recorded |
| Reg. No. 28/5.8/0231 | Flustat | Syrup | Not recorded |
| Reg. No. Y/5.8/264 | Adco-sinal co | Tablet | Not recorded |
Safety Considerations
- Cardiovascular and stroke risk: Phenylpropanolamine was withdrawn from the US market around 2000 because of hemorrhagic stroke risk. Its current regional marketing status should be verified. This concern also limits the case for pursuing any new indication.
Please refer to the SAHPRA-approved Professional Information (PI) for full warnings, contraindications and interactions. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no trial or literature support (L5), and the top-ranked indication probably overlaps with existing decongestant use. The stroke-related safety history is a further reason not to advance.
To proceed, the following is needed:
- The SAHPRA package insert (PI) for the registered products, to confirm approved indications, warnings and contraindications
- Confirmation of whether nasal cavity disease is already a labelled indication (which would make it a known use, not repurposing)
- A benefit-risk review of hemorrhagic stroke risk in the South African regulatory context
- Mechanism of action data from DrugBank
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.